DS
PRLD icon

David Shaw’s Prelude Therapeutics PRLD Stock Holding History

David Shaw’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-49,184
Closed -$152K – 4547
2023
Q3 		$152K Sell
49,184
-6,654
-12% -$25K ﹤0.01% 3802
2023
Q2 		$251K Buy
55,838
+8,589
+18% +$51.3K ﹤0.01% 3664
2023
Q1 		$269K Sell
47,249
-20,756
-31% -$127K ﹤0.01% 3788
2022
Q4 		$411K Sell
68,005
-10,876
-14% -$69.7K ﹤0.01% 3961
2022
Q3 		$521K Sell
78,881
-36,986
-32% -$249K ﹤0.01% 4021
2022
Q2 		$605K Buy
115,867
+92,256
+391% +$470K ﹤0.01% 3990
2022
Q1 		$163K Buy
+23,611
New +$216K ﹤0.01% 4919
2021
Q2 		– Sell
-12,546
Closed -$544K – 4959
2021
Q1 		$544K Buy
+12,546
New +$832K ﹤0.01% 3465

Other funds holding PRLD

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

David Shaw's PRLD Position: Q4 2023 in Review

David Shaw sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 49,184 shares — an estimated $152K sold.

David Shaw first reported a position in PRLD in Q1 2021 and held it in 8 quarters. The position peaked at $605K in Q2 2022. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

  • David Shaw reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
  • David Shaw sold 49,184 Prelude Therapeutics shares in Q4 2023, an estimated $152K.
  • David Shaw first reported a position in Prelude Therapeutics in Q1 2021 and held it in 8 quarters.
  • David Shaw's Prelude Therapeutics position peaked at $605K in Q2 2022.
  • 56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on D.E. Shaw & Co's 13F filing for Q4 2023, filed 14 Feb 2024.